Measured in a serum-free cell proliferation assay using MCF7 human breast cancer cells. The ED50 for this effect is less than 0.5 ng/ml.
LR3-IGF-I Protein, Porcine
LR3-IGF-I Protein, Porcine
Price:
Regular price
$44.00 USD
Regular price
Sale price
$44.00 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Porcine |
| Synonyms | LR3 Insulin-like Growth Factor-I; MGF; IGFI; IGF1A; IGF; IBP1; |
| Accession | P16545 |
| Amino Acid Sequence | Gly49-Ala118 (Glu51Arg) |
| Expression System | E.coli |
| Molecular Weight | 9 kDa (Reducing) |
| Purity | >95% by SDS-PAGE. |
| Endotoxin | <1EU/μg |
| Conjugation | Unconjugated |
| Tag | No Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | 20mM NaAC, 20mM HAC, pH4.5 |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
| Reference | Carlson S W. et al. (2018) Central Infusion of Insulin-Like Growth Factor-1 Increases Hippocampal Neurogenesis and Improves Neurobehavioral Function after Traumatic Brain Injury. J Neurotrauma. 35(13):1467-1480. |
Background
IGF-I is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-I is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-II, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-I (rhLR3-IGF-I) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3-IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3) and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.
Picture
Picture
Bioactivity
SDS-PAGE
2μg (R: reducing condition, N: non-reducing condition).
